AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019

Nina Ditsch, Michael Untch, Marc Thill, Volkmar Müller, Wolfgang Janni, Ute-Susann Albert, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall, Ingo Diel, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Volker Hanf, Nadia Harbeck, Jens Huober, Christian Jackisch, Cornelia Kolberg-Liedtke, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Volker Möbus, Markus Müller-Schimpfle, Christoph Mundhenke, Ulrike Nitz, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Frederik Wenz, Isabell Witzel, Achim Wöckel, Nina Ditsch, Michael Untch, Marc Thill, Volkmar Müller, Wolfgang Janni, Ute-Susann Albert, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall, Ingo Diel, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Volker Hanf, Nadia Harbeck, Jens Huober, Christian Jackisch, Cornelia Kolberg-Liedtke, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Volker Möbus, Markus Müller-Schimpfle, Christoph Mundhenke, Ulrike Nitz, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Frederik Wenz, Isabell Witzel, Achim Wöckel

No abstract available

Keywords: Early breast cancer; Local therapy; Systemic therapy; Treatment recommendations.

Conflict of interest statement

The conflict of interest statements of all authors with conflicts of interest can be found in the supplementary material (see www.karger.com/doi/10.1159/000501000).

Figures

Fig. 1

Indications for primary axillary lymph node dissection.

Fig. 2

Possible associations between implants and rare diseases.

Fig. 3

Algorithm for decision-making in cases with an indication for breast reconstruction.

Fig. 4

Subtype-specific strategies for systemic treatment indicating the recommendation to add pertuzumab only among cases with increased risk.

Fig. 5

Residual disease after neoadjuvant systemic therapy – treatment recommendations.

Fig. 6

Ovarian protection and fertility preservation in premenopausal patients receiving (neo)adjuvant chemotherapy.